Clinical Trial

Evaluation of Outcomes Following In-office Tympanostomy Using the Tula® System: a Prospective, Multi-center Registry

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 23, 2024 (before its estimated March 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This prospective, single-arm, multicenter registry is being conducted to collect real world post-market data from patients aged from 6 months to 17 years of age who are undergoing an in-office ear tube placement procedure (tympanostomy) using the Tula® System. The Registry will include up to 20 centers in the US and up to 200 patients for the initial evaluation. The FDA-approved Tula System includes the Tula Iontophoresis System (IPS) with TYMBION™ otic anesthetic for local anesthesia of the ear drum and the Tula Tube Delivery System (TDS) for ear tube placement. Clinical research established the safety, efficacy and tolerability of this system for in-office procedures in the pediatric population. Patients will be treated and evaluated according to standard medical care. Outcome data is collected up to 6 months following extrusion or removal of their tube(s).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-13; most recent amendment 2024-07-19.
Status change: Not Yet Recruiting → Recruiting 2023-07-06
Trial Details
NCT Number NCT05915078
Lead Sponsor Smith & Nephew, Inc.
Conditions Otitis Media With Effusion, Acute Otitis Media, Otitis Media
Enrollment 200 participants
Start Date 2023-06-15
Primary Completion 2025-03-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-23